The uPAR System as a Potential Therapeutic Target in the Diseased Eye

Cells. 2019 Aug 18;8(8):925. doi: 10.3390/cells8080925.

Abstract

Dysregulation of vascular networks is characteristic of eye diseases associated with retinal cell degeneration and visual loss. Visual impairment is also the consequence of photoreceptor degeneration in inherited eye diseases with a major inflammatory component, but without angiogenic profile. Among the pathways with high impact on vascular/degenerative diseases of the eye, a central role is played by a system formed by the ligand urokinase-type plasminogen activator (uPA) and its receptor uPAR. The uPAR system, although extensively investigated in tumors, still remains a key issue in vascular diseases of the eye and even less studied in inherited retinal pathologies such as retinitis pigmantosa (RP). Its spectrum of action has been extended far beyond a classical pro-angiogenic function and has emerged as a central actor in inflammation. Preclinical studies in more prevalent eye diseases characterized by neovascular formation, as in retinopathy of prematurity, wet macular degeneration and rubeosis iridis or vasopermeability excess as in diabetic retinopathy, suggest a critical role of increased uPAR signaling indicating the potentiality of its modulation to counteract neovessel formation and microvascular dysfunction. The additional observation that the uPAR system plays a major role in RP by limiting the inflammatory cascade triggered by rod degeneration rises further questions about its role in the diseased eye.

Keywords: angiogenesis; animal models; co-receptor signaling; inflammation; ocular diseases; photoreceptor degeneration; retinal function; uPAR system blockade; vascular leakage.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Disease Models, Animal
  • Humans
  • Inflammation / drug therapy*
  • Mice
  • Mice, Inbred BALB C
  • Neovascularization, Pathologic / drug therapy*
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Urokinase Plasminogen Activator* / antagonists & inhibitors
  • Receptors, Urokinase Plasminogen Activator* / physiology
  • Retinal Diseases* / drug therapy
  • Retinal Diseases* / metabolism
  • Retinal Diseases* / pathology
  • Urokinase-Type Plasminogen Activator* / antagonists & inhibitors
  • Urokinase-Type Plasminogen Activator* / physiology

Substances

  • Receptors, Urokinase Plasminogen Activator
  • Urokinase-Type Plasminogen Activator